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Abstract
Background: Methylergonovine is an ergot alkaloid widely used in postpartum women. It is also
an active metabolite of methysergide and previous studies suggest that it could be effective against
refractory headache and cluster headache. The purpose of the present study was to assess the
potential therapeutic effectiveness of methylergonovine in the emergency treatment of severe
migraine.
Methods: One hundred and twenty five female patients with migraine attending the emergency
department received 0.15 mg of methylergonovine intravenously. Pain intensity, heart rate, blood
pressure, and methylergonovine side effects were checked 5, 10, 15, 30 and 60 minutes after drug
administration. An additional 0.075 mg dose of methylergonovine was administered to those
patients who did not experienced relevant pain relief 15 minutes after dosing. 
Results: Pain intensity decreased markedly from the first minutes after dosing, the 74.4% of
patients being pain free at 60 minutes. Only seven patients required an additional dose of
methylergonovine. Nausea and vomiting were the most relevant side effects related with
methylergonovine administration (84% of patients). A substantial decrease (10 to 25 mmHg) in
systolic blood pressure values was observed in 56% of the patients. A significant correlation (p <
0.0001) was found between the decrease in pain intensity and the reduction of systolic blood
pressure.
Conclusion: Although limited by the non-controlled design of the study, our data suggest that
intravenous methylergonovine can be an effective and safe drug in the management of severe
migraine attacks in the emergency room.
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Background
The treatment of migraine attacks in the emergency room
includes the use of several kind of drugs, usually adminis-
tered by parenteral route, namely non-steroidal antiin-
flamatory drugs (NSAIDs), opioids, glucocorticoids,
neuroleptics, ergot alkaloids and triptans [1]. Among
ergot alkaloids, dihydroergotamine, available as intrana-
sal, subcutaneous, intramuscular or intravenous formula-
tions, has been shown to be effective and well tolerated
[2], and its intravenous administration has been advo-
cated in the management of status migrainosus [3]. How-
ever, dihydroergotamine, which is a cheap and effective
drug for the acute therapy of migraine attacks, is only
available in few countries.
Methylergonovine, also called methylergometrine, is
another ergot alkaloid, a semisynthetic derivative of LSD,
widely used in the postpartum for its uterotonic proper-
ties. Additionally, methylergonovine is also a major active
metabolite of methysergide whose area under the curve
after oral administration of methysergide is substantially
higher than the one of the parent drug [4]. Methylergono-
vine has been postulated to play an important role in the
methysergide therapeutic efficacy in migraine [5]. Earlier
publications have shown that oral administration of
methylergonovine could be effective in the control of the
drug induced refractory headache [6] as well as in the
management of cluster headache [7].
The purpose of the present study was to evaluate the
potential effectiveness of intravenous methylergonovine
in the acute treatment of severe migraine previously
refractory to non-steroidal analgesic drugs (NSAID).
Methods
The study was done in the Emergency Departments of two
hospitals of the district of Santa Marta, in Colombia.
Inclusion criteria were female adult patients experiencing
migraine with or without aura according to the IHS diag-
nostic criteria [8], and suffering an attack of severe inten-
sity (≥8 in a 10 cm Visual Analog Scale) who attended the
emergency room because the pain had not improved with
their usual home treatment. Every patient provided writ-
ten informed consent to participate in the study.
Women experiencing current or previous cardiovascular
disease, morbid obesity, epilepsy, serious (DSM IV Axis I)
psychiatric disease, known intolerance to ergot alkaloids,
pregnant or lactating were excluded from the study, as
well as those who have received ergotamine or triptans in
the previous twenty four hours.
Pain intensity was assessed by means of a Visual Analog
Scale (VAS) just before drug administration and 5, 10, 15,
30 and 60 minutes after. Arterial blood pressure and heart
frequency were measured, and emergent drug adverse
reactions were recorded at the same time points. Methyl-
ergonovine was administered intravenously diluted in 5
ml of saline at an initial dosage of 0.15 mg. If pain inten-
sity was still above 5 in pain VAS, an additional dose of
0.075 mg of methylergonovine was administered 15 min-
utes after the first one. Analgesic drug intake before admis-
sion was recorded. In fourteen (11%) patients, randomly
selected, continuous monitoring of the ECG was per-
formed during the all the observation period.
Data were analyzed by means of GraphPad Prism version
5.0 (GraphPad Software, San Diego, California, USA,
http://www.graphpad.com.). Repeated measures analysis
of variance was applied to analyze the evolution of pain
severity, systolic and diastolic blood pressure, and heart
rate. Effects sizes were caluculated according to the
Cohen's formula and considered large when equal or
higher than 0.80 [9]. Comparison between data from
patients requiring one and two doses of methylergono-
vine was done with the Student's t test for unpaired data.
The Spearmen correlation coefficients were used to evalu-
ate the potential relationship between systolic blood pres-
sure and pain intensity.
Results
One hundred and twenty five patients participated in the
study. One hundred and eleven (88.8%) suffered
migraine without aura and 14 (11.2%) migraine with
aura. Their age ranged from 25 to 45 years (45 ± 7). All
patients reported photophobia, phonophobia, nausea
and vomiting at baseline. Previous analgesic intake
included paracetamol (55%), aspirin (16%), ibuprofen
(16%), metamizole (9,6%), diclofenac (8%), and com-
bined analgesics (6.4%).
Pain intensity subsided quickly after methylergonovine
administration until reaching a mean value of 0.46 ± 1.1
60 minutes after dosing. As it can be seen in Figure 1, the
decrease in pain severity was statistically significant and
clinically relevant already 5 minutes after drug injection.
Only seven (5.6%) patients required a second additional
dose of methylergonovine 15 minutes after the initial one.
As it is shown in Figure 2, although baseline pain severity
was similar among patients who needed only one dose of
methylergonovine and those who needed two doses (9.91
± 0.32 vs 9.86 ± 0.38, not significant), final pain intensity
was significantly higher at endpoint among the later
group (0.25 ± 0.51 vs 4 ± 2, p < 0.0001).
Complete disappearance of pain was reached by 66
(52.8%) patients 30 minutes after dosing and by 93Head & Face Medicine 2009, 5:21 http://www.head-face-med.com/content/5/1/21
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(74.4%) patients 60 minutes after dosing. Only one of the
patients requiring an additional dose of methylergono-
vine was pain free at 60 minutes.
Table 1 shows arterial blood pressure and heart frequency
data. Neither blood pressure nor heart frequency
increased in any patient. On the contrary, a reduction in
mean baseline systolic blood pressure values was
observed along the time (Figure 3). A significant correla-
tion(r = 0.2817, p < 0.0001) was found between the
change in systolic blood pressure and the decrease in pain
intensity (Figure 4). No electrocardiographic abnormali-
ties were found in any of the patients whose ECG was
monitored.
Nausea (84.8%) and vomiting (84%) were the most fre-
quent side effects related with methylergonovine admin-
istration, followed by fatigue (34.4%), diaphoresis
(12%), and dizziness (11.2%). Seventy two (57.6%)
patients reported perceptive alterations, mainly sensation
to be floating, sensation of peacefulness, and feelings of
pleasant relaxation.
Discussion
Intravenous methylergonovine originated a quick and
strong relief of pain in our patients. The degree of
improvement, either considering the mean VAS score 60
minutes after dosing or the percentage of patients experi-
encing total pain relief, was similar to the improvement
described with the use of intravenous prochlorperazine, a
Pain intensity over the monitored time period (***: p <  0.0001 in relation to baseline; ES: effect size) Figure 1
Pain intensity over the monitored time period (***: p 
< 0.0001 in relation to baseline; ES: effect size).
Pain intensity over the monitored time period in patients  receiving one (grey bars) or two doses (black bars) of methy- lergonovine Figure 2
Pain intensity over the monitored time period in 
patients receiving one (grey bars) or two doses 
(black bars) of methylergonovine.
Evolution of systolic blood pressure values over the moni- tored period Figure 3
Evolution of systolic blood pressure values over the 
monitored period.
Correlation among individual changes in pain intensity and  systolic blood pressure Figure 4
Correlation among individual changes in pain inten-
sity and systolic blood pressure.Head & Face Medicine 2009, 5:21 http://www.head-face-med.com/content/5/1/21
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conventional antipsychotic, in several randomized clini-
cal trials [10-12].
It is difficult to compare our data with those published for
dihydoergotamine because, with only one exception in
which it was found to be less effective than chlopro-
mazine [13], this drug has been administered either by
intramuscular route compared with subcutaneous
sumatriptan, or associated with an antiemetic, usually
metoclopramide which is known to exert an antimigraine
activity of its own [14,15]. A recent systematic review of
trials performed with dihydroergotamine concluded that,
associated with an antiemetic, it seems to be as effective as
the other active comparators, but underlined that the
methodology and scientific quality of the trials was highly
variable [15].
The fact that only one of the seven patients who received
an additional dose of methylergonovine achieved com-
plete pain relief, suggests that little or no drug benefit can
be expected in initially nonresponder patients.
Most frequent methylergonovine side effect is hyperten-
sion, hypotension having been described less frequently
[16]. However, none of our patients experienced an
increase in blood pressure. On the contrary, a clinically
relevant decrease in systolic blood pressure values, rang-
ing from 10 to 25 mmHg without relevant changes in
diastolic blood pressure, was observed in 70 (56%)
patients 60 minutes after drug administration. As tran-
sient hypertension has been described associated with
migraine attacks [17], we thought that the observed reduc-
tion in systolic blood pressure could be related with pain
relief. The fact that a significant correlation was found
between individual changes in systolic blood pressure and
pain relief (Figure 4) supports this explanation.
Nausea and vomiting have been reported to occur occa-
sionally following methylergonovine administration
[16]. In our sample these were the most frequent adverse
event reported by our patients. However, as all of them,
suffered these symptoms associated to their migraine
attack at hospital arrival, it is difficult to ascertain if nau-
sea and vomiting were due to the effect of the drug or to
the underlying disease.
In our study men with migraine were excluded because
methylergonovine, as an uterotonic drug, is basically used
in women, and data concerning its pharmacological activ-
ity in men are lacking. Methylergonovine pharmacokinet-
ics has been studied in women and in men: no differences
between them were found when the drug was adminis-
tered intravenously and, after oral administration, the
wide interindividual variation in pharmacokinetic param-
eters did not allowed to compare adequately both groups
[18]. Additionally, pharmacodynamic differences could
exist and influence both drug efficacy and tolerability, for
instance at cardiovascular level.
The main limitation of our study is its non-controlled
design due to the difficulties to carry out a controlled ran-
domized clinical trial in Colombia, where this kind of
studies are not easily performed if they are not sponsored
by a international pharmaceutical company, mainly due
to financial reasons. However, we think that the sample
size of our study, the pronounced effect over pain, and the
low interindividual variability of the data support the con-
sistency of our results.
An additional limitation is the fact that patients were dis-
missed from the hospital 30 minutes after the last evalua-
tion, and were not followed later to assess headache
recurrence. Methylergonovine half-life is short - 1.94 ±
0.34 hours after i.v. administration in women [18] and
recurrence rate should have been assessed.
There is a need for effective and low cost drugs for the
acute treatment of severe migraine and status migraino-
sus. Sumatriptan is a very effective but expensive drug.
Opioids are scarcely effective and most headache special-
ists advise against their use [19]. Although dexametha-
sone seems to be effective in reducing migraine attack's
recurrence, its efficacy to decrease attack's pain is similar
to placebo [20]. Some conventional neuroleptics, as
prochlorperazine and chlorpromazine, have been used by
parenteral route in the acute management of migraine
[21], being akathisia is the most common side effect asso-
ciated with intravenous prochlorperazine and postural
Table 1: Range, mean and SD values of blood pressure and heart 
rate during the monitored period
Systolic BP Diastolic BP Heart rate
Baseline (100-130)
114.7-6.47
(55-80)
61.5 ± 3.95
(60-88)
72.8 ± 4.9
5 minutes (98-120)
107.3-4.78
(55-75)
60.9 ± 3.83
(60-82)
69.5 ± 5.6
10 minutes (95-122)
106.6 ± 4.67
(51-75)
60.4 ± 3.9
(55-82)
68.5 ± 5.5
15 minutes (95-120)
105.7 ± 4.86
(51-75)
59.8 ± 3.9
(55-82)
67.8 ± 5.3
30 minutes (95-117)
104.8 ± 4.46
(54-76)
59.6 ± 3.7
(53-80)
67.5 ± 5.1
60 minutes (95-117)
104.5 ± 4.43
(54-75)
59.7 ± 3.4
(53-80)
67.4 ± 4.8
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hypotension with chlorpromazine. Dihydroergotamine
seems to be especially effective only when associated to an
antiemetic and, on the other hand, is not available world-
wide. Methylergonovine is available in many countries,
both in oral and parenteral formulations, and has a very
low acquisition cost, a factor which is very important,
especially for developing countries. Randomized control-
led trials in patients of both sexes seem to be warranted in
order to ascertain its potential role in the acute manage-
ment of migraine.
Conclusion
Despite the above mentioned limitations, we think that
our results suggest that intravenous methylergonovine, at
least in the medium dose used in this study, can be an
effective and safe drug in the emergency management of
severe refractory migraine, and in an environment with
limited access to health resources could be an alternative
to triptans.
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